Marc Gittelman, MD
Urology · Aventura, FLNPI 1174587604
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,281 of the $22,205 with a category attached, or 82.3%. Boehringer Ingelheim accounts for 66.3% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $15,462 and has fallen 97.1% since, to $447 in 2025.
Across 135 payments — averaging $164.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$15K
- Clarus Therapeutics Inc.$4K
- Janssen Scientific Affairs, LLC$1K
- Myriad Genetic Laboratories, Inc.$563
- Astellas Pharma US Inc$496
- Johnson & Johnson$337
- plus $1K from 22 others
Across 39 payments — averaging $5498.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$123K
- OPKO Pharmaceuticals, LLC$55K
- Boston Scientific$23K
- Ferring Pharmaceuticals AS$9K
- Janssen Research & Development, LLC$3K
- Ferring International Pharmascience Center US$1K
What the payments were for
- Consulting fees$1,1005%
- Speaking & faculty fees$18,28182%
- Food & beverage$2,82413%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 4 | $14,731 |
| Clarus Therapeutics Inc. | 3 | $3,550 |
| Janssen Scientific Affairs, LLC | 1 | $1,100 |
| Myriad Genetic Laboratories, Inc. | 20 | $563 |
| Astellas Pharma US Inc | 23 | $496 |
| Johnson & Johnson | 31 | $337 |
| BD | 2 | $246 |
| Endo Pharmaceuticals Inc. | 10 | $199 |
| Boston Scientific | 4 | $159 |
| AbbVie | 2 | $146 |
| Tolmar Pharmaceuticals, Inc. | 6 | $115 |
| Pfizer | 3 | $66 |
| Coloplast | 4 | $66 |
| Ferring Pharmaceuticals Inc. | 3 | $64 |
| Verity Pharmaceuticals Inc. | 3 | $60 |
| Merck | 2 | $48 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| Olympus America Inc. | 2 | $32 |
| Bayer | 1 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Endo USA, Inc. | 1 | $23 |
| Halozyme Inc | 1 | $19 |
| Tolmar, Inc. | 1 | $19 |
| Laborie Medical Technologies Corp. | 1 | $16 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $15 |
| Mission Pharmacal Company | 1 | $15 |
| Angiodynamics, Inc. | 1 | $15 |
| Amniox Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- APTIVUS$14,731
- JATENZO$10,650
- Erleada$1,100
- Magic3 Go Intermittent Urinary Catheter$208
- Lupron Depot$125
- XTANDI$125
- REZUM$112
How this compares
$22,205 in reported general payments places this provider in the 85th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 42 | $50,198 |
| GemtesaVibegron | 45 | $44,869 |
| Tamsulosin Hcl | 193 | $2,819 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 86 | $2,583 |
| Methenamine Hippurate | 34 | $2,396 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 175 | $1,614 |
| Testosterone Cypionate | 34 | $1,129 |
| Finasteride | 65 | $1,118 |
| Silodosin | 19 | $1,117 |
| Testosterone | 11 | $789 |
| Estradiol | 13 | $725 |
| Tadalafil | 20 | $723 |
| Dutasteride | 14 | $596 |
| Sildenafil Citrate | 55 | $277 |
| Oxybutynin Chloride ErOxybutynin Chloride | 13 | $267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $496 | $50,19842 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $42 | $44,86945 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 935 urology providers in Florida.
Other urology in Aventura
- Jonathan SilbersteinAventura$216K
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
- Olubayo TojuolaOrlando$283K
- Juan SuarezCoral Gables$276K
- Michael McDonaldCelebration$272K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.